Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Tuesday session in green amid volatile trading. The shares closed up +0.39 points or 1.51% at $26.28 with 11.98 million shares getting traded. Post opening the session at $25.98, the shares hit an intraday low of $25.69 and an intraday high of $26.49 and the price vacillated in this range throughout the day. The company has a market cap of $9.27 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
Valeant Pharmaceuticals Intl Inc (VRX) develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails.
Shares of Emergent Biosolutions Inc (NYSE:EBS) ended Tuesday session in green amid volatile trading. The shares closed up +0.40 points or 1.42% at $28.50 with 238,014.00 shares getting traded. Post opening the session at $28.01, the shares hit an intraday low of $27.98 and an intraday high of $28.50 and the price vacillated in this range throughout the day. The company has a market cap of $1.14 billion and the numbers of outstanding shares have been calculated to be 40.46 million shares.
Emergent Biosolutions Inc (EBS) develops, manufactures, and sells specialized products to healthcare providers and governments in the United States and internationally. The companys Biodefense division markets BioThrax to treat anthrax disease; Anthrasil for the treatment of inhalational anthrax; BAT to treat botulinum disease; VIGIV to address the adverse events from smallpox vaccination; and RSDL for the removal or neutralization of chemical agents, T-2 toxins, and various pesticide-related chemicals from the skin. This division is also developing NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072, the compound in the EV-035 series of broad spectrum antibiotics for Burkholderia pseudomallei; VAX161C, a recombinant pandemic influenza vaccine; and PreviThrax, a recombinant protective antigen anthrax vaccine, as well as other products addressing public health threats and emerging infectious diseases.